Plaquenil Side Effects
Generic name: hydroxychloroquine
Medically reviewed by Drugs.com. Last updated on Nov 20, 2023.
Note: This document contains side effect information about hydroxychloroquine. Some dosage forms listed on this page may not apply to the brand name Plaquenil.
Applies to hydroxychloroquine: oral tablet.
Serious side effects of Plaquenil
Along with its needed effects, hydroxychloroquine (the active ingredient contained in Plaquenil) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking hydroxychloroquine:
Incidence not known
- Anxiety
- black, tarry stools
- bleeding gums
- blindness
- blistering, peeling, loosening of the skin
- blood in the urine or stools
- blurred vision or other vision changes
- change in how colors look
- chest discomfort, pain, or tightness
- chills
- cold sweats
- confusion
- cough or hoarseness
- dark urine
- decreased urination
- defective color vision
- diarrhea
- difficulty seeing at night
- dilated neck veins
- dizziness or fainting
- fast, pounding, uneven heartbeat
- feeling that others are watching you or controlling your behavior
- feeling that others can hear your thoughts
- feeling, seeing, or hearing things that are not there
- fever
- headache
- inability to move the eyes
- increased blinking or spasms of the eyelid
- increased hunger
- joint or muscle pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, and sex organs
- loss of hearing
- lower back or side pain
- nervousness
- nightmares
- noisy breathing
- painful or difficult urination
- pale skin
- palpitations
- pinpoint red spots on the skin
- red irritated eyes
- red skin lesions, often with a purple center
- seizures
- severe mood or mental changes
- shakiness
- slurred speech
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- sticking out of the tongue
- stomach pain
- swelling of the eye
- swelling of the face, fingers, feet, or lower legs
- swollen or painful glands
- trouble with breathing, speaking, or swallowing
- uncontrolled twisting movements of the neck, trunk, arms, or legs
- unusual behavior
- unusual bleeding or bruising
- unusual facial expressions
- unusual tiredness or weakness
- weight gain
- yellow eyes or skin
Get emergency help immediately if any of the following symptoms of overdose occur while taking hydroxychloroquine:
Symptoms of overdose
- Drowsiness
- dry mouth
- increased thirst
- loss of appetite
- mood changes
- no pulse or blood pressure
- numbness or tingling in the hands, feet, or lips
- unconsciousness
Other side effects of Plaquenil
Some side effects of hydroxychloroquine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
- Continuing ringing or buzzing or other unexplained noise in the ears
- darkening of the skin
- feeling of constant movement of self or surroundings
- hair loss or thinning of the hair
- increased sensitivity of the skin to sunlight
- irritability
- loss of appetite
- nausea
- redness or other discoloration of the skin
- sensation of spinning
- severe sunburn
- shakiness and unsteady walk
- uncontrolled eye movements
- unsteadiness, trembling, or other problems with muscle control or coordination
- vomiting
- weight loss
For Healthcare Professionals
Applies to hydroxychloroquine: compounding powder, oral tablet.
Cardiovascular
Rare (0.01% to 0.1%): Cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome),
Frequency not reported: Arrhythmia (torsade de pointes, ventricular tachycardia), conduction disorders (bundle branch block/atrioventricular heart block), biventricular hypertrophy, QT interval prolongation, ventricular arrhythmias, torsade de pointes, sick sinus syndrome, pulmonary hypertension[Ref]
QT interval prolongation has been reported in patients with specific risk factors, which may lead to arrhythmia (torsade de pointes, ventricular tachycardia).[Ref]
Ocular
Common (1% to 10%): Blurred vision (including due to disturbance of accommodation)
Uncommon (0.1% to 1%): Retinopathy (with changes in pigmentation, visual field defects), retinal changes (including paracentral, pericentral ring types, temporal scotomas, abnormal color vision), corneal changes (including edema, opacities), haloes, photophobia
Very rare (less than 0.01%): Extraocular muscle palsies
Frequency not reported: Maculopathies, macular degeneration, abnormal macular pigmentation and depigmentation (sometimes with bull's eye appearance), pallor of optic disc, optic atrophy, narrowing of retinal arterioles
Postmarketing reports: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas), visual disturbances (visual acuity), maculopathies (macular degeneration), decreased dark adaptation, color vision abnormalities, corneal changes (edema, opacities), corneal deposition of drug with or without accompanying symptoms (halo around lights, photophobia, blurred vision[Ref]
Blurred vision (temporary) and extraocular muscle palsies (reversible) were due to disturbance of accommodation, which was dose dependent and reversible.
Retinopathy appeared to be uncommon when the recommended daily dose was not exceeded. In its early form, it appeared reversible when therapy was discontinued. If allowed to develop, there was risk of progression even after treatment withdrawal.
Patients with retinal changes were asymptomatic initially or had scotomatous vision with paracentral, pericentral ring types, temporal scotomas, and abnormal color vision.
Corneal changes (including edema and opacities) have occurred from 3 weeks (infrequently) to some years after starting therapy. These changes were either symptomless or caused disturbances such as haloes, blurred vision, or photophobia; they may be transient and were reversible when therapy was discontinued.
Maculopathies and macular degeneration have been reported (onset ranging from 3 months to several years of exposure to this drug) and may be irreversible.[Ref]
Gastrointestinal
Very common (10% or more): Abdominal pain, nausea
Common (1% to 10%): Diarrhea, vomiting[Ref]
In general, abdominal pain, nausea, diarrhea, and vomiting resolved immediately when the dose was reduced or therapy was stopped.[Ref]
Dermatologic
Common (1% to 10%): Skin rash, pruritus, alopecia
Uncommon (0.1% to 1%): Pigmentary changes, pigmentation disorders in skin and mucous membranes, bleaching of hair
Rare (0.01% to 0.1%): Attacks of psoriasis
Very rare (less than 0.01%): Dermatitis bullous eruptions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, photosensitivity, exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP)
Frequency not reported: Urticaria, angioedema
Postmarketing reports: Hair color changes[Ref]
In general, skin rash, pruritus, pigmentation disorders in skin and mucous membranes, bleaching of hair, and alopecia resolved readily when therapy was discontinued.
AGEP had to be distinguished from psoriasis, although this drug has precipitated attacks of psoriasis. AGEP has been associated with fever and hyperleukocytosis. In general, outcome was favorable after stopping this drug.[Ref]
Metabolic
Common (1% to 10%): Anorexia
Rare (0.01% to 0.1%): Exacerbation/precipitation of porphyria
Postmarketing reports: Hypoglycemia, decreased appetite, porphyria[Ref]
Nervous system
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Dizziness, nerve deafness, vertigo, tinnitus
Rare (0.01% to 0.1%): Seizure/convulsions, neuromyopathy
Very rare (less than 0.01%): Nystagmus, ataxia
Frequency not reported: Hearing loss
Postmarketing reports: Extrapyramidal disorders (e.g., dystonia, dyskinesia, tremor), deafness[Ref]
Psychiatric
Common (1% to 10%): Affect/emotional lability
Uncommon (0.1% to 1%): Nervousness
Very rare (less than 0.01%): Psychosis, suicidal behavior, nightmares
Postmarketing reports: Irritability[Ref]
Hepatic
Uncommon (0.1% to 1%): Abnormal liver function tests
Very rare (less than 0.01%): Fulminant hepatitis
Postmarketing reports: Acute/fulminant hepatic failure[Ref]
Musculoskeletal
Myopathy has been reversible after therapy discontinuation, but recovery has taken many months.[Ref]
Uncommon (0.1% to 1%): Sensorimotor disorders
Frequency not reported: Absent/hypoactive deep tendon reflexes
Postmarketing reports: Skeletal muscle myopathy/muscle weakness/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups), depression of tendon reflexes, abnormal nerve conduction studies[Ref]
Hematologic
Rare (0.01% to 0.1%): Bone-marrow failure/depression, anemia, aplastic anemia, leukopenia, thrombocytopenia
Very rare (less than 0.01%): Agranulocytosis
Postmarketing reports: Hemolysis (in glucose-6-phosphate dehydrogenase deficient patients)[Ref]
Other
Very rare (less than 0.01%): Weight decreased/loss, fatigue/lassitude[Ref]
Respiratory
Postmarketing reports: Bronchospasm[Ref]
Hypersensitivity
Frequency not reported: Allergic reactions (urticaria, angioedema, bronchospasm), hypersensitivity myocarditis[Ref]
Frequently asked questions
- An Update: Is hydroxychloroquine effective for COVID-19?
- Does hydroxychloroquine cause emotional lability?
More about Plaquenil (hydroxychloroquine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (158)
- Latest FDA alerts (2)
- Dosage information
- During pregnancy
- Generic availability
- Support group
- Drug class: antimalarial quinolines
- Breastfeeding
- En español
Patient resources
Professional resources
Other brands
Related treatment guides
References
1. (2022) "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc
2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
3. Cerner Multum, Inc. "Australian Product Information."
4. (2017) "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.